Clinical Trials Logo

ALK Gene Rearrangement Positive clinical trials

View clinical trials related to ALK Gene Rearrangement Positive.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03779191 Completed - Clinical trials for Non-Squamous Non-Small Cell Neoplasm of Lung

Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Start date: April 8, 2020
Phase: Phase 2
Study type: Interventional

This single-arm, open-label, phase II clinical study aims to evaluate the progression-Free Survival (PFS) of the combination of Alectinib plus Bevacizumab in untreated and first and second-line chemotherapy failed subjects with stage IIIB/IV or recurrent disease after receiving radiation therapy or surgical resection. The main question to be answered is: Whether the combination of Alectinib plus Bevacizumab will improve PFS in untreated and previously treated subjects with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and positive ALK translocation. Participants will be treated with Alectinib and Bevacizumab every three weeks until disease progression, unacceptable toxicity, or patient withdrawal of consent.

NCT ID: NCT03727477 Completed - Clinical trials for Non-small Cell Lung Cancer Metastatic

Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib

LORLATU
Start date: February 1, 2019
Phase:
Study type: Observational

The study will evaluate progression-free survival, overall survival, best response and duration of treatment in patients with advanced ALK- and ROS1-positive non-small cell lung cancer who received lorlatinib as part of the French expanded access program.